OSE and its pharma partners have made progress with all clinical and preclinical assets. The final analysis of the data from the Phase III ATALANTE-1 study (investigating its off-the-shelf neoepitope-based cancer vaccine Tedopi in NSCLC) revealed a potential path to market, and OSE initiated the registrational Phase III ARTEMIA trial in September 2024. OSE’s IL-7R-targeting antibody therapy, lusvertikimab, recently completed a Phase II study in ulcerative colitis showing statistically significant benefits; the full data set will be presented in due course. OSE is also focused on the clinical development of OSE-279, an anti-PD1 blocking monoclonal antibody being investigated for the treatment of advanced solid tumours or lymphomas. OSE has shared initial positive signs of safety and efficacy from a Phase I/II trial and we expect further readouts in H224. The three partnered programmes – BI 765063/BI 7770371, FR104/VEL-101 and ABBV-230 – are at different stages of clinical development and generate relatively steady licensing fee income.